Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Cara Therapeutics (CARA)

Cara Therapeutics (CARA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 17,063
  • Shares Outstanding, K 54,847
  • Annual Sales, $ 20,970 K
  • Annual Income, $ -118,510 K
  • EBIT $ -108 M
  • EBITDA $ -107 M
  • 60-Month Beta 0.68
  • Price/Sales 0.86
  • Price/Cash Flow N/A
  • Price/Book 1.54
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -2.04
  • Most Recent Earnings $-0.37 on 08/14/24
  • Next Earnings Date 11/18/24 [--]
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 416.28% ( -339.72%)
  • Historical Volatility 63.81%
  • IV Percentile 48%
  • IV Rank 23.93%
  • IV High 1,285.41% on 06/13/24
  • IV Low 142.92% on 05/13/24
  • Put/Call Vol Ratio 999.99
  • Today's Volume 1
  • Volume Avg (30-Day) 17
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 460
  • Open Int (30-Day) 350

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.17
  • Number of Estimates 2
  • High Estimate -0.10
  • Low Estimate -0.25
  • Prior Year -0.59
  • Growth Rate Est. (year over year) +71.19%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2508 +16.03%
on 10/24/24
0.3685 -21.03%
on 11/08/24
+0.0259 (+9.77%)
since 10/18/24
3-Month
0.2450 +18.78%
on 10/10/24
0.3720 -21.77%
on 08/26/24
-0.0438 (-13.08%)
since 08/16/24
52-Week
0.2400 +21.25%
on 06/20/24
1.3100 -77.79%
on 12/15/23
-0.8090 (-73.55%)
since 11/17/23

Most Recent Stories

More News
Cara: Q3 Earnings Snapshot

Cara: Q3 Earnings Snapshot

CARA : 0.2925 (-5.98%)
Cara: Q2 Earnings Snapshot

Cara: Q2 Earnings Snapshot

CARA : 0.2925 (-5.98%)
Cara: Q1 Earnings Snapshot

Cara: Q1 Earnings Snapshot

CARA : 0.2925 (-5.98%)
Cara: Q4 Earnings Snapshot

Cara: Q4 Earnings Snapshot

CARA : 0.2925 (-5.98%)
Mira Pharmaceuticals Stock Is Soaring In November... Here's Why

Leveraging a favorable DEA classification for its synthetic analog of THC, Mira Pharmaceuticals could be on an expedited pathway toward commercialization to treat several unmet neurological m

MIRA : 1.4100 (-8.44%)
CARA : 0.2925 (-5.98%)
CRBP : 16.76 (+0.90%)
HRMY : 33.07 (-0.44%)
JAZZ : 117.59 (-3.34%)
Cara: Q3 Earnings Snapshot

Cara: Q3 Earnings Snapshot

CARA : 0.2925 (-5.98%)
Cara: Q2 Earnings Snapshot

Cara: Q2 Earnings Snapshot

CARA : 0.2925 (-5.98%)
Kapruvia® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus

/CNW/ -- Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that England's National Institute for...

CARA : 0.2925 (-5.98%)
Kapruvia® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus

/PRNewswire/ -- Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that England's National Institute...

CARA : 0.2925 (-5.98%)
Cara: Q1 Earnings Snapshot

Cara: Q1 Earnings Snapshot

CARA : 0.2925 (-5.98%)

Business Summary

Cara Therapeutics, Inc. is a biopharmaceutical company. The company is focused on developing and commercializing new chemical entities designed to alleviate pain. Cara Therapeutics, Inc. is based in Shelton, United States.

See More

Key Turning Points

3rd Resistance Point 0.3641
2nd Resistance Point 0.3470
1st Resistance Point 0.3291
Last Price 0.2925
1st Support Level 0.2941
2nd Support Level 0.2770
3rd Support Level 0.2591

See More

52-Week High 1.3100
Fibonacci 61.8% 0.9013
Fibonacci 50% 0.7750
Fibonacci 38.2% 0.6487
Last Price 0.2925
52-Week Low 0.2400

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar